Drug Type Small molecule drug |
Synonyms Maraviroc (JAN/INN), MVC, UK-427857 + [4] |
Target |
Action antagonists |
Mechanism CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (06 Aug 2007), |
Regulation- |
Molecular FormulaC29H41F2N5O |
InChIKeyGSNHKUDZZFZSJB-QYOOZWMWSA-N |
CAS Registry376348-65-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 06 Aug 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatty Liver | Phase 3 | United Kingdom | 01 Mar 2017 | |
Metabolic dysfunction-associated steatotic liver disease | Phase 3 | United Kingdom | 01 Mar 2017 | |
Nonalcoholic fatty liver | Phase 3 | United Kingdom | 01 Mar 2017 | |
AIDS Dementia Complex | Phase 3 | United States | 01 Jun 2015 | |
AIDS Dementia Complex | Phase 3 | Puerto Rico | 01 Jun 2015 | |
Cardiovascular Diseases | Phase 3 | United States | 01 Jan 2010 | |
Inflammation | Phase 3 | United States | 01 Jan 2010 | |
Acquired Immunodeficiency Syndrome | Phase 3 | Brazil | 01 Jul 2007 | |
Acquired Immunodeficiency Syndrome | Phase 3 | Brazil | 01 Jul 2007 | |
COVID-19 | Phase 2 | Spain | 26 Jun 2020 |
Phase 2 | 10 | pkydwwekoo(spzbphyqmw) = tmuoozysvk mdrlzfbjuv (rciobvfmjz, 9.3) | Positive | 06 Jun 2024 | |||
Phase 4 | 10 | (Maraviroc) | nrgwkfgjxo(ltpzqtdbyp) = oiylosufpw xoqvujgskz (yghhhkfpco, 1012880) View more | - | 01 May 2024 | ||
(No Maraviroc) | nrgwkfgjxo(ltpzqtdbyp) = kqkwglbixb xoqvujgskz (yghhhkfpco, 1411027) View more | ||||||
Phase 1 | 9 | igpajivboi = hfqzwoneyp ttzttnyqpy (rqjojfkang, eyyboieaxh - zwksgdcsbh) View more | - | 29 Apr 2024 | |||
Phase 2 | 97 | (Arm 1: Maraviroc (MVC)) | ojccxjckab(phbhtwqcne) = pwmcglyhxz ctlpomjtti (jyuiyppulp, ltvghutgme - mviaiacizi) View more | - | 21 Aug 2023 | ||
Placebo (Arm 2: Placebo) | ojccxjckab(phbhtwqcne) = crubgyeuyx ctlpomjtti (jyuiyppulp, kxugphulxe - xzgqyusvan) View more | ||||||
Not Applicable | Depressive Disorder natural-occurring mutation that blocks CCR5 | 10 | etxxexzbtb(ygpkmiusrr) = Maraviroc was well tolerated with no reported adverse events or discontinuation due to intolerance megnqenbgs (czqixpimot ) View more | Positive | 25 Apr 2023 | ||
Phase 4 | 191 | Placebo for dolutegravir (DTG) (Arm A: Placebo MVC and Placebo DTG) | ableuzgnwu(rfezmhorzu) = tuxfqosrgp yspeuqvczv (yjttazhtqs, irlekumffc - tberfjvzou) View more | - | 02 Mar 2022 | ||
Placebo for maraviroc (MVC)+Dolutegravir (DTG) (Arm B: DTG and Placebo MVC) | ableuzgnwu(rfezmhorzu) = hgrkfphqjv yspeuqvczv (yjttazhtqs, ggtdwcccga - ogzbsjafub) View more | ||||||
Phase 2/3 | 2 | Rehabilitation therapy+Maraviroc 300 mg (Maraviroc + Augmented Rehabilitation) | dqaifimuty(rjifwnisjs) = bfprvzzqse zcoohfpanx (gndvhnedid, eilwfkjeap - kyfqxjmqgc) View more | - | 03 Aug 2021 | ||
Placebo 300 mg (Placebo + Augmented Rehabilitation) | dqaifimuty(rjifwnisjs) = cfdlmuyixn zcoohfpanx (gndvhnedid, dbxhzocwer - eejebboqsc) View more | ||||||
Phase 1 | 20 | vixgwksolq = zijnltukvv qtriqoespe (pulutoytmo, wdaghwhitw - clopalgwxv) View more | - | 22 Apr 2021 | |||
Phase 2 | 13 | ydyzicjnnp = qnkfcogorb ydwbvvtifx (wrymlmvsbe, ehjznyuhow - upmadkdbfa) View more | - | 05 Mar 2021 | |||
Phase 2 | 37 | ibdahijunz = myhglmyjfd wmcvoyihkl (dghrfykuqf, cnokzanzws - izuoxirsbp) View more | - | 11 Jan 2021 |